Introduction

Risk Evaluation and Mitigation Strategies (REMS) are regulatory measures designed to ensure that the benefits of a medicine outweigh its risks. They are particularly relevant to drugs that may cause serious adverse effects, even when used correctly. A REMS may require special warnings, patient education, prescriber training, restricted distribution, laboratory monitoring, or proof that particular safety steps have been completed before a medicine is supplied.

REMS is a specific United States regulatory framework created under the Food and Drug Administration Amendments Act, 2007. It is important to distinguish this system from India’s drug-safety framework: India does not use the identical US REMS mechanism, but it regulates medicine safety through the Drugs and Cosmetics Act, 1940, applicable rules, pharmacovigilance, and conditions imposed by drug regulators.

The legality of risk-mitigation measures depends on whether they are authorised by statute, supported by safety evidence, proportionate to the risk, and implemented with appropriate procedural safeguards. Such measures must protect patients without imposing unnecessary barriers to access to essential medicines.

Statutory Basis and Legal Limits

Under 21 U.S.C. § 355-1, the US Food and Drug Administration (FDA) may require a REMS when necessary to ensure that a drug’s benefits outweigh its risks. A strategy may include medication guides, communication plans, or “elements to assure safe use,” such as provider certification, patient monitoring, or controlled dispensing. The FDA must assess whether the requirements are necessary and consider their effect on access to treatment.

U.S. Code+2

The statute also imposes safeguards. Safety requirements must be proportionate to the particular serious risk and must not be unduly burdensome to patient access, especially for people with serious illnesses or limited access to healthcare. REMS requirements can be reviewed and modified when evidence or circumstances change.

U.S. Code+1

FDA guidance helps explain how the agency applies these statutory factors, but guidance itself is generally nonbinding and does not independently create enforceable obligations.

FDA+1

Case Laws

1. Alliance for Hippocratic Medicine v. FDA, 602 U.S. 367 (2024)

The US Supreme Court dismissed the challenge to FDA actions concerning mifepristone because the plaintiffs lacked standing. The case did not decide the substantive legality of the drug’s REMS or resolve the merits of the FDA’s regulatory decisions.

Its importance is therefore limited but significant: challenges to medicine-safety regulation must satisfy constitutional standing requirements. The decision should not be cited as a ruling that the mifepristone REMS was either lawful or unlawful.

Fourth Circuit Court

2. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

The Indian Supreme Court held that medical consent must be voluntary and based on adequate information about the nature, purpose, benefits, substantial risks, and alternatives of treatment.

Although the case did not concern the US REMS system, it supports the legal principle underlying risk-mitigation programmes: patient safety measures should enable informed decision-making, not merely impose formal requirements.

Indian Kanoon+1

3. Vellore Citizens’ Welfare Forum v. Union of India, (1996) 5 SCC 647

The Supreme Court recognised the precautionary principle in environmental law. It provides an analogous basis for taking preventive action where there is a credible risk of serious harm, even if scientific certainty is incomplete.

Applied by analogy to pharmaceutical safety, this principle supports monitoring, warnings, and restrictions where serious risks are reasonably identified. However, precautionary action must remain rational and evidence-based.

Indian Regulatory Position

India does not have a directly equivalent statutory REMS framework. Its drug-safety system includes the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, CDSCO oversight, and the Pharmacovigilance Programme of India. The 2024 pharmacovigilance guidance for marketing authorisation holders addresses safety monitoring, periodic safety update reports, and risk management plans where applicable.

29.8.2024.cdr+1

Conclusion

REMS legality depends on statutory authority, evidence of serious risk, proportionality, and continued review. The US framework under 21 U.S.C. § 355-1 permits targeted safeguards while requiring attention to patient access. In India, similar objectives are pursued through pharmacovigilance and drug-regulatory controls rather than an identical REMS system. The principles of informed consent, precaution, and proportionate regulation provide useful legal foundations, but Indian cases should be treated as analogous—not as direct judgments on US REMS legality.